SurModics to present four scientific posters on drug delivery technologies at CRS Annual Meeting

SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society (CRS), July 10-14, 2010 in Portland, Oregon (booth #521). SurModics announced that it is presenting four scientific posters on its drug delivery technologies:

“As a leader in drug delivery and surface modification technologies, SurModics is committed to providing proven technologies to our partners and to helping accelerate the commercialization process with clinically important products.”

• Peter Markland, Ph.D, Director of New Technologies, is presenting Sustained Release Microparticle Formulations Administered Through Small-Bore Needles Useful for Intraocular Applications (poster 237) on Monday, July 12 from 1:00-2:00 PM. The poster describes novel microparticle compositions that can be administered through smaller-diameter needles than standard biodegradable microparticle formulations. These novel compositions allow for administration using smaller gauge needles which can improve patient compliance, especially for routes of administration that are particularly sensitive to needle diameter such as ocular delivery. 
• Parissa Heshmati, Ph.D, Senior Scientist, is presenting Use of Anionic and Cationic Surfactants in Poly(Lactide-co-Glycolide) Nanoparticle Production (poster 337) on Monday, July 12 from 1:00-2:00 PM. The poster demonstrates the use of a variety of anionic and cationic surface active agents replacing the widely used poly(vinyl alcohol) surfactant in nanoparticle production.
• Joram Slager, Ph.D, Staff Scientist, is presenting Long Term Protein Delivery from Organogel Formulations (poster 379) on Monday, July 12 from 1:00-2:00 PM. The poster shows long term and tunable release of antibodies from an in situ gelling delivery system based on SurModics' Eureka^TM SOLO polymer platform. These hydrophobic gels, either physically or chemically crosslinked, have the advantage of a relative ease of administration and the potential for incorporating high pay-loads of therapeutic proteins.
• Joe McGonigle, Ph.D, Senior Engineer, is presenting Controlled Release of Bioactive Cationic Lipid/siRNA Complexes from Implantable and Injectable Hydrogel Matrices (poster 635) on Tuesday, July 13 from 1:00-2:00 PM. The poster demonstrates that SurModics' Eureka^TM DUET polymer platform can be used for sustained release of cationic lipid/siRNA complexes which retain high levels of gene knockdown activity.

"These posters demonstrate SurModics' innovative drug delivery technologies, enabling delivery in new therapeutic areas and improved routes of administration. Additionally, they showcase our expertise in delivering novel therapeutic classes such as proteins and siRNA," said Phil Ankeny, Interim CEO. "As a leader in drug delivery and surface modification technologies, SurModics is committed to providing proven technologies to our partners and to helping accelerate the commercialization process with clinically important products."

SOURCE SurModics, Inc.